GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DICE Therapeutics Inc (NAS:DICE) » Definitions » 3-Year Revenue Growth Rate

DICE Therapeutics (DICE Therapeutics) 3-Year Revenue Growth Rate : 0.00% (As of Jun. 2023)


View and export this data going back to 2021. Start your Free Trial

What is DICE Therapeutics 3-Year Revenue Growth Rate?

DICE Therapeutics's Revenue per Share for the three months ended in Jun. 2023 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Competitive Comparison of DICE Therapeutics's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, DICE Therapeutics's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DICE Therapeutics's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DICE Therapeutics's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where DICE Therapeutics's 3-Year Revenue Growth Rate falls into.


DICE Therapeutics 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

DICE Therapeutics  (NAS:DICE) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

DICE Therapeutics 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of DICE Therapeutics's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

DICE Therapeutics (DICE Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DICE Therapeutics Inc (NAS:DICE) » Definitions » 3-Year Revenue Growth Rate
Comparable Companies
CINC CTIC GOSS AMRN CHRS PHVS ITOS SRNE RLMD AAGH OCSE:NOVO B ASX:CSL REGN VRTX MRNA XKRX:207940 BNTX HKSE:02269 SGEN SZSE:300122
Traded in Other Exchanges
N/A
Address
400 East Jamie Court, Suite 300, South San Francisco, CA, USA, 94080
Website
https://www.dicetherapeutics.com
DICE Therapeutics Inc is a biopharmaceutical company leveraging proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. The company is initially focused on developing oral therapeutics against well-validated targets in immunology, with the goal of achieving comparable potency to systemic biologic counterparts, which have demonstrated the greatest therapeutic benefit to date in these disease areas.
Executives
Northpond Ventures Gp, Llc 10 percent owner 7500 OLD GEORGETOWN ROAD, SUITE 850, BETHESDA MD 20814
John R. Jacobsen officer: CSO C/O DICE THERAPEUTICS, INC., 279 E. GRAND AVENUE, SUITE 300, LOBBY B, SOUTH SAN FRANCISCO CA 94080
Richard H Scheller director C/O GENENTECH INC, 1 DNA WAY MS 49, SOUTH SAN FRANCISCO CA 94080-4990
Scott M. Robertson officer: CFO & CBO C/O DICE THERAPEUTICS, INC., 279 E. GRAND AVENUE, SUITE 300, LOBBY B, SOUTH SAN FRANCISCO CA 94080
Lu Timothy officer: CMO C/O DICE THERAPEUTICS, INC., 279 E. GRAND AVENUE, SUITE 300, LOBBY B, SOUTH SAN FRANCISCO CA 94080
Kevin Judice director, officer: CEO 6310 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Ra Capital Healthcare Fund Lp director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
James Paul Scopa director 601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Lisa Bowers director C/O DICE THERAPEUTICS, INC., 279 E. GRAND AVENUE, SUITE 300, LOBBY B, SOUTH SAN FRANCISCO CA 94080
Mittie Doyle director C/O DICE THERAPEUTICS, INC., 279 E. GRAND AVENUE, SUITE 300, LOBBY B, SOUTH SAN FRANCISCO CA 94080
Michael P. Rubin 10 percent owner 7500 OLD GEORGETOWN ROAD, SUITE 850, BETHESDA MD 20814
Shaan-chirag C Gandhi director NORTHPOND VENTURES, 7500 OLD GEORGETOWN ROAD, BETHESDA MD 20814
Northpond Ventures Ii, Lp 10 percent owner 7500 OLD GEORGETOWN ROAD, SUITE 850, BETHESDA MD 20814
Northpond Ventures Gp Ii, Llc 10 percent owner 7500 OLD GEORGETOWN ROAD, SUITE 850, BESTHESDA MD 20814
Stephen Zachary director C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902